Myeloma News
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma
Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes
Enhancing diagnostic accuracy of multiple myeloma through ML-driven analysis of hematological slides: new dataset and identification model to support hematologists
Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
Source: Pharmacy Times articles
Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.
Read More
The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
FCRL5-Directed CAR T-Cell Therapy: A Novel Therapeutic Approach for Multiple Myeloma
Source: Pharmacy Times articles
CAR T-cells specifically targeting FCRL5, when integrated with IL-15, may improve cytotoxicity, thereby enhancing the therapeutic potency of these cells.
Read More
Expert: Pharmacists Have Vital Role in Multiple Myeloma Treatment
Source: Pharmacy Times articles
The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.
Read More
Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Recent Publications
T Cell Exhaustion Markers in Multiple Myeloma Patients are Lower After Physical Activity Intervention
Clin Lymphoma Myeloma Leuk. 2024 Apr 26:S2152-2650(24)00153-8. doi: 10.1016/j.clml.2024.04.006. Online ahead of print. ABSTRACT PURPOSE: There is compelling evidence that CD4+ and CD8+T cells are dysfunctional in multiple myeloma, compromising their ability to control disease progression....
Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma
Biofactors. 2024 May 17. doi: 10.1002/biof.2078. Online ahead of print. ABSTRACT Multiple myeloma (MM) is a blood cancer caused by uncontrolled growth of clonal plasmacells. Bone disease is responsible for the severe complications of MM and is caused by myeloma cells infiltrating the bone marrow...
Personalized Treatment of Multiple Myeloma in Frail Patients
Curr Oncol Rep. 2024 May 18. doi: 10.1007/s11912-024-01545-2. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: As the treatment landscape for multiple myeloma (MM) continues to expand at a rapid pace, management of older adults and frail patients becomes increasingly challenging. As these...
Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis
Clin Lymphoma Myeloma Leuk. 2024 Apr 19:S2152-2650(24)00154-X. doi: 10.1016/j.clml.2024.04.005. Online ahead of print. ABSTRACT INTRODUCTION: The therapeutic landscape in relapsed/refractory multiple myeloma (RRMM) has changed rapidly, with twenty-two drug approvals since 2012. We characterized...
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Blood Cancer J. 2024 May 17;14(1):82. doi: 10.1038/s41408-024-01062-2. ABSTRACT Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable...
Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma
Biomed Pharmacother. 2024 May 16;175:116738. doi: 10.1016/j.biopha.2024.116738. Online ahead of print. ABSTRACT Despite significant advancements in multiple myeloma (MM) treatment in recent years, most patients will eventually develop resistance or experience relapse. Matrine, a primary active...
Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241252605. doi: 10.1177/15330338241252605. ABSTRACT OBJECTIVE: 1q21 gain/Amp is one of the most common cytogenetic abnormalities. There are controversies about its effects on prognosis and may be associated with inferior outcomes in patients with...
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
Expert Opin Biol Ther. 2024 May 17. doi: 10.1080/14712598.2024.2357382. Online ahead of print. ABSTRACT INTRODUCTION: Gain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
